US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CAR-T Concept

1,730.74

-3.1686-0.18%

Number of Gainers:1

Number of Losers:1

Number of Flat:- -

PE:- -

High:1,732.48

Open:1,732.01

Low:1,705.45

Close:1,733.91

Volume:6.90M

Turnover:988.71M

Market Cap:446.00B

Float Cap:437.73B

Loading ...

Novartis AG Falls Wednesday, Outperforms Market

Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says

MT Newswires Live

Novartis Shouldn't Rush to Cover Upcoming Patent Expirations

RBC Initiates Novartis at Sector Perform With CHF120 Price Target

MT Newswires Live

Novartis's Stock Selloff Looks Overdone

Novartis Faces Sales Hole in Early 2030s After Trial Setback

Amgen Shares Plunge to Decade Low After Rival Drug Trial Fails, BMO Cuts Rating

European Shares Steady as Drugmaker Rout Offsets Commodity Strength

Gilead Sciences Inc. Stock Underperforms Tuesday When Compared to Competitors

Asia Morning Call-Global Markets

US Equity Markets End Lower After Houthi Attack on Saudi Arabia Energy Facilities

MT Newswires Live

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for Hsv Helicase-Primase Inhibitor Program

THOMSON REUTERS

Assembly Biosciences - Assembly Bio Eligible for up to $280 Mln in Milestones and Royalties Outside U.S.

THOMSON REUTERS

Assembly Biosciences - Gilead Retains Sole Right for Clinical Development and Commercialization of Hsv Hpi Program

THOMSON REUTERS

Top Midday Decliners

MT Newswires Live

Jefferies says definitive readthrough to Sarepta from Novartis news ‘premature’

Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Sep 8: Drivers Behind the Movement

Mizuho sees Sarepta selloff on Novartis DM1 miss as overdone

Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says

MT Newswires Live

Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/BK4578/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BK4578","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","market":"US","secType":"PLATE","nameCN":"CAR-T Concept","latestPrice":1730.7407,"timestamp":1789502399999,"preClose":1733.9093,"halted":0,"volume":6903229,"delay":0,"changeRate":-0.001827,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-3.168579,"latestTime":"09-15 16:00:00 EDT","open":1732.0104,"high":1732.4797,"low":1705.446,"amount":988711146.759969,"amplitude":0.015591,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789545600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":8.300443,"peRate":46.548588,"turnoverRate":0.002235,"increases":0,"decrements":2,"flats":0,"marketCap":445998383104,"floatMarketCap":437728854016},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","high":1732.4797,"amplitude":0.015591,"preClose":1733.9093,"low":1705.446,"pbRate":"8.300443","latestPrice":1730.7407,"volume":6903229,"delay":0,"open":1732.0104,"prevYearClose":1612.5378,"prevWeekClose":1707.2908,"prevMonthClose":1830.2803,"prevQuarterClose":1768.1697,"fiveDayClose":1725.5667,"twentyDayClose":1794.044,"sixtyDayClose":1684.6451,"secType":"PLATE","market":"US","turnoverRate":0.002235,"peRate":46.548588,"marketCap":445998383104,"floatMarketCap":437728854016,"timestamp":1789502399999,"nameCN":"CAR-T Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4578\",,,,undefined,":{"bkCode":"BK4578","up":1,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4578\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666531005","title":"Novartis AG Falls Wednesday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2666531005","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666531005?lang=en_us&edition=fundamental","pubTime":"2026-09-10 00:15","pubTimestamp":1788970500,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novartis AG  slipped 0.1% to CHF111.66 Wednesday on what proved to be an overall unfavorable trading session for the stock market, with the Swiss Market Index SMI Index  falling 1.8% to 13,804.70.Novartis AG closed CHF21.02 below its 52-week high of CHF132.68, which the company achieved on September 3, 2026.Trading volume was 4,314,570, compared to the 50-day average trading volume of 2,451,167.Data source: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0208291251.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","NVS","BK4585","IE0009355771.USD","LU0211331839.USD","MEDX","LU0320765489.SGD","BK4532","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","BK4007","PPH","BK4578","IE00B2B36J28.USD","BK4588","LU0070302665.USD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666539005","title":"Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2666539005","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666539005?lang=en_us&edition=fundamental","pubTime":"2026-09-09 23:10","pubTimestamp":1788966641,"startTime":"0","endTime":"0","summary":"Dyne Therapeutics  investment thesis remains intact despite a setback for Novartis  in a phase 3 trial for myotonic dystrophy type 1, as differences in drug targeting, payload and clinical strategy could lead to different outcomes, RBC Capital Markets said in a Tuesday note.According to the analysts, Dyne's approach uses an antibody fragment rather than a full-length antibody, an antisense oligonucleotide rather than small interfering RNA, and a six month primary endpoint versus 12 months for Novartis' trial.RBC said Dyne remains confident in its phase 3 study, with data expected in Q1 2027.Dyne is also running a confirmatory phase 3 study using the five times sit-to-stand test as its primary endpoint, providing a second opportunity to achieve statistical significance, the note said.The analysts also see a potential catalyst in Dyne's DMD51 program, with a US Food and Drug Administration decision expected Jan. 21, 2027.RBC maintained its outperform rating on Dyne Therapeutics and lower","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BJJMRZ35.SGD","DYN","BK4139","BK4505","IE00BJT1NW94.SGD","NVS","IE00BFTCPJ56.SGD","LU0211331839.USD","IE00B4R5TH58.HKD","BK4007","IE0002141913.USD","MEDX","IE00B2B36J28.USD","IE0009355771.USD","BK4585","LU0320765489.SGD","BK4532","BK4578","LU0208291251.USD","BK4588","PPH","LU0070302665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666253906","title":"Novartis Shouldn't Rush to Cover Upcoming Patent Expirations","url":"https://stock-news.laohu8.com/highlight/detail?id=2666253906","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666253906?lang=en_us&edition=fundamental","pubTime":"2026-09-09 23:07","pubTimestamp":1788966420,"startTime":"0","endTime":"0","summary":"1507 GMT - Recent clinical-trial setbacks mean Novartis needs to be near-flawless in bringing the rest of its pipeline to the market or look for deals, but the Swiss drugmaker shouldn't rush it, RBC Capital Markets analysts say in a research note. \"Shares have pulled back from all-time highs, but we see no urgency to act,\" the analysts say. The failures of cardiovascular and neuromuscular drugs pelacarsen and del-desiran raise the bar for Novartis's pipeline, given that these were two important candidates to offset sales lost to upcoming patent expirations, they add. RBC starts coverage on the stock with a sector perform recommendation and a target price of 120 Swiss francs. Shares fall 0.3% to 111.44 francs.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","BK4578","NVS","MEDX","BK4588","LU0211331839.USD","LU0320765489.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","PPH","BK4585","IE00BJT1NW94.SGD","BK4532","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0208291251.USD","LU0070302665.USD","BK4007","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666847965","title":"RBC Initiates Novartis at Sector Perform With CHF120 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2666847965","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666847965?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:29","pubTimestamp":1788949792,"startTime":"0","endTime":"0","summary":"Novartis's (NVS) Swiss stock has an average rating of hold and mean price target of CHF125.60, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B2B36J28.USD","BK4578","IE00B4R5TH58.HKD","BK4532","IE00BFTCPJ56.SGD","IE0009355771.USD","MEDX","BK4007","BK4585","LU0208291251.USD","LU0320765489.SGD","LU0070302665.USD","NVS","PPH","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0211331839.USD","IE00BJT1NW94.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666854435","title":"Novartis's Stock Selloff Looks Overdone","url":"https://stock-news.laohu8.com/highlight/detail?id=2666854435","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666854435?lang=en_us&edition=fundamental","pubTime":"2026-09-09 16:24","pubTimestamp":1788942240,"startTime":"0","endTime":"0","summary":"0823 GMT - Novartis's stock selloff on the failure of a neuromuscular drug in a clinical trial looks overdone and upcoming study results could be more positive for the Swiss drugmaker, Citi analysts say in a research note. The company reiterated its 2025-2030 outlook and trial setbacks for experimental neuromuscular and heart drugs del-desiran and pelacarsen are partially mitigated by the success of its remibrutinib medicine in a multiple sclerosis study, the analysts say. Full data for the MS study and results from another trial for the same drug in skin condition hidradenitis suppurativa could play in Novartis's favor, they add. Citi cuts its target price on Novartis stock to 135 Swiss francs from 142 francs. Shares fall 1.1% to 110.54 francs, after closing 11% lower Tuesday.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211331839.USD","BK4588","NVS","IE00BJT1NW94.SGD","LU0208291251.USD","BK4532","BK4585","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","MEDX","BK4578","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","BK4007","IE0009355771.USD","LU0320765489.SGD","LU0070302665.USD","IE0002141913.USD","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666158379","title":"Novartis Faces Sales Hole in Early 2030s After Trial Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2666158379","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666158379?lang=en_us&edition=fundamental","pubTime":"2026-09-09 16:01","pubTimestamp":1788940860,"startTime":"0","endTime":"0","summary":"0801 GMT - Novartis's latest clinical-trial setback raises questions about the Swiss drugmaker's acquisition track record and leaves a sales hole to be plugged in the early 2030s, Deutsche Bank's Emmanuel Papadakis says in a research note. News that drug candidate del-desiran missed the target of a late-stage study in rare neuromuscular disorder known as myotonic dystrophy type 1 came shortly after cardiovascular drug pelacarsen failed another trial. Del-desiran was the first proof point for the recent $12 billion Avidity acquisition, the analyst says. Moreover, it leaves a hole to be addressed in the early 2030s when big drugs like Cosentyx, Kisqali and Kesimpta lose patent protection, he adds. Deutsche Bank cuts its recommendation on Novartis stock to hold from buy and trims its target price to 120 Swiss francs from 140 francs. Shares fall 0.8% to 110.86 francs.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Novartis Faces Sales Hole in Early 2030s After Trial Setback","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","NVS","MEDX","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","BK4585","IE0009355771.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU0070302665.USD","BK4578","BK4588","LU0320765489.SGD","BK4532","IE00BFTCPJ56.SGD","PPH","LU0208291251.USD","BK4007","LU0211331839.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189130455","title":"Amgen Shares Plunge to Decade Low After Rival Drug Trial Fails, BMO Cuts Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1189130455","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189130455?lang=en_us&edition=fundamental","pubTime":"2026-09-09 14:48","pubTimestamp":1788936492,"startTime":"0","endTime":"0","summary":"Amgen shares tumbled more than 10% on Tuesday, marking their worst single-day decline since 2016, after Novartis AG revealed that a heart disease therapy it is developing with Ionis Pharmaceuticals...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242646821.SGD","BK4533","LU1061106388.HKD","LU0109394709.USD","NVS","LU1983299246.USD","LU0320765489.SGD","LU1057294990.SGD","LU0320765992.SGD","LU0289739699.SGD","BK4534","LU0208291251.USD","LU2468319806.SGD","IE00B4R5TH58.HKD","IBBQ","LU0122379950.USD","LU1571399168.USD","BK4532","BK4578","BK4588","IE0002141913.USD","BK4581","LU1023059063.AUD","LU2089984988.USD","BK4599","IBB","PJP","TBXU","IE00BFTCPJ56.SGD","PBE","BK4007","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","BK4566","MEDX","LU2112291526.USD","BBH","LU0868494617.USD","BK4585","PPH","LU2242652126.USD","BIB","LU0058720904.USD","IE00BJT1NW94.SGD","IE0009355771.USD","BK4139","LU0070302665.USD","LU0211331839.USD","AMGN","LU0889565916.HKD","SG9999001440.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131780980","title":"European Shares Steady as Drugmaker Rout Offsets Commodity Strength","url":"https://stock-news.laohu8.com/highlight/detail?id=1131780980","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131780980?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:52","pubTimestamp":1788900732,"startTime":"0","endTime":"0","summary":"European equity markets found their footing on Tuesday, with the benchmark index holding its ground even as a heavyweight pharmaceutical firm experienced a record slump.The Stoxx Europe 600 index...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","JHMD","MFDX","EPIN","AVDE","EFAX","IMOM","PXF","BINV","BKCI","STXI","OAIM","ICPY","GLBL","IFV","EAFG","BK4581","IAUG","OPPE","DINT","GIEQ","IEFA","IE00B2B36J28.USD","DBEU","YSEP","IJAN","AVNM","HFXI","SEIE","IE00BJT1NW94.SGD","BK4585","VEFA","AVSD","FINT","RODE","ENHI","TACN","LU0070302665.USD","MOTI","IE00BJJMRZ35.SGD","TILC","IDJN","XEML","YMAR","BUFY","FEDM","IEV","DFAX","PTEU","TIIV","IJUL","IEUR","BK4007","IAPR","PTIN","ISWN","IQSI","VEU","EFZ","BUFI","BK4167","RFDI","TOK","GSEU","IXUS","IMAR","QLVD","EPV","RINT","EFO","INOV","PPIE","RFEU","VGK","BK4578","GXUS","IMTM","TLCI","BBIN","NVS","VIDI","MEDX","JULI","UIVM","DDWM","FDT","ESIM","IE00B4R5TH58.HKD","CGXU","HAWX","BKIE","KOKU","FENI","SPDW","UPV","BK4532","PQIN","RODM","IDUB","JANI","IBUF","EASG","ISDX","DWMF","RAYD","CGIE","DBEF","JDVI","BAIV","DMXU","BK4582","URTH","BK4534","ITOL","XEUR","CEFA","CGIC","WCMI","WCMG","IOCT","ARLI","FEP","GLOF","DFAI","CWI","OVF","FFDI","PIEQ","QBIF","FSZ","IQDF","LU0208291251.USD","EFA","TLTD","BK4588","EURL","IQLT","LU0211331839.USD","IVSI","HEFA","FHIL","TOUS","IDEC","OEFA","SSXU","IVAL","ILOW","DTAN","FIEE","TDI","LU0320765489.SGD","IFEB","JIRE","VEA","SPEU","GSID","DEEF","FLEE","PGRI","DMXF","IDEV","INTF","MFSI","IFLR","BRIE","ACWX","PZIV","IDMO","VNIE","AIVI","TXUE","IDEQ","PIZ","IE0009355771.USD","AVIV","QBIV","YDEC","GSIE","NBIE","IMAY","BK4020","NIHI","XW","IDME","PDEV","JPIN","BBEU","NUDM","FEZ","EWN","IDMY","PPH","SCHF","WWJD","IJUN","EUDG","RDMX","BK4550","APIE","IGGY","QEFA","IMFL","AFDM","FEOE","REFA","BK4504","ISEP","IE00BFTCPJ56.SGD","FDEV","ICOW","TPIF","DXIV","DFIC","CVIE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666416377","title":"Gilead Sciences Inc. Stock Underperforms Tuesday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2666416377","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666416377?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:35","pubTimestamp":1788899700,"startTime":"0","endTime":"0","summary":"DJ Gilead Sciences Inc. Stock Underperforms Tuesday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Gilead Sciences Inc.  slid 2.88% to $146.64 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index  falling 0.58% to 7,673.52 and Dow Jones Industrial Average  falling 1.18% to 52,786.07.This was the stock's second consecutive day of losses.Gilead Sciences Inc. closed 6.77% below its 52-week high of $157.29, which the company reached on February 11th.The stock underperformed when compared to some of its competitors Tuesday, as Johnson & Johnson  fell 2.22% to $269.12, Pfizer Inc.  fell 2.32% to $27.79, and Abbott Laboratories  fell 2.59% to $105.52.Trading volume  remained 673,543 below its 50-day average volume of 6.7 M.Data source: Dow Jones Market Data, FactSet. Data compiled September 8, 2026.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","LU1066051498.USD","IE00B3T34201.USD","LU0823416689.USD","BIB","LU1430594728.SGD","LU2087621335.USD","SG9999015978.USD","BMED","BK4578","LU1839511570.USD","BK4588","LU0859254822.USD","BBH","LU0965509101.SGD","LU0122379950.USD","LU0320765992.SGD","IBB","IE00B19Z3B42.SGD","LU1061106388.HKD","LU1066053197.SGD","LU1778281490.HKD","LU0965509010.AUD","LU1571399168.USD","LU1057294990.SGD","SG9999015945.SGD","LU0882574055.USD","LU1934455194.USD","LU2357627491.SGD","IE00B19Z3581.USD","IBBQ","IE00BKVL7J92.USD","BK4568","LU0234570918.USD","GILD","LU0058720904.USD","LU0889565916.HKD","LU1037948897.HKD","LU2324357040.USD","MEDI","SG9999015986.USD","SG9999015952.SGD","LU1674673428.USD","BK4139","LU0965508806.USD","LU0109394709.USD","LU0289739699.SGD","LU1585245621.USD","LU1934455277.USD","TBXU","LU1674673691.USD","IE00BSNM7G36.USD","BK4532","IE00BZ1G4Q59.USD","BK4550","LU1934455863.HKD","BK4583","LU0861579265.USD","IE00B7SZLL34.SGD","LU1037948541.HKD","TMED","LU1023059063.AUD","BK4585","LU0965509283.SGD","LU2112291526.USD","BK4566","LU2089984988.USD","IE0002270589.USD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377919","title":"Asia Morning Call-Global Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377919","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377919?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:30","pubTimestamp":1788899401,"startTime":"0","endTime":"0","summary":"UPDATE 1-Asia Morning Call-Global MarketsSept 9 (Reuters)-Stock MarketsNet ChngStock MarketsNet ChngS&P/ASX 200**8920.8-90.1NZX 50**13792.9-149.93DJIA**52828.61-585.64NIKKEI**65269.33-1130.51Nasdaq**2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4N4501KQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0006306889.USD","07200","LU2458330169.SGD","BK4607","IE00B19Z8W00.USD","LU2361044949.HKD","LU0792757196.USD","LU0130102774.USD","IE00B2B36J28.USD","LU0198837287.USD","LU0889566641.SGD","MAXI","LU0211327993.USD","LU1951200564.SGD","BK4527","000001","CBOO","QBF","83115","IE00B19Z8X17.USD","BPI","CRM","LU1366333091.USD","EZBC","LU0528227936.USD","BK4532","LU0511384066.AUD","02833","LU1496350171.SGD","MCHmain","CBTJ","BK4561","LU1791710400.SGD","LU2361044865.SGD","BITB","LU1548497426.USD","LU1923623000.USD","LU0353189763.USD","LU0289961442.SGD","LU0472753341.HKD","LU2265009873.SGD","LU0052756011.USD","LU1720051017.SGD","IE00B19Z9505.USD","BK4023","IE0002141913.USD","LU0689626769.HKD","LU1655091616.SGD","DJIA","BK4579","BETE","HSI","BK4535","BITO","HHImain","LU0069063385.USD","FBTC","BK4581","LU0314104364.USD","LU1951198990.SGD","BK4613","IBIT","CBOA","LU0127658192.USD","MNRS","LU0130518102.USD","LU0267386448.USD","LU0130517989.USD","LU1201861165.SGD","LU2236285917.USD","LU0081259029.USD","LU1993786604.SGD","BETH","BK4598","LU0106261372.USD","IE00BJTD4V19.USD","LU0353189680.USD","BFAP","CBTA","LU1989764664.SGD","LU0187121727.USD","LU0689472784.USD","LU1267930490.SGD","03115","BITY","LU0820561909.HKD","STI.SI","LU0648000940.SGD","513600","LU0648001328.SGD","ARKB","LU0070302665.USD","BK4608","HSTECH","LU0234572021.USD","IE00B4R5TH58.HKD","BK0183","IE00BJTD4N35.SGD","HODL","LU0557290698.USD","LU1046421795.USD","BTCC","CBOY","LU1803068979.SGD","LU0048573561.USD","LU1814569148.SGD","LU0130103400.USD","BK4538","BITX","LU0251142724.SGD","IE00BQXX3D17.EUR","LU0124676726.USD","LU0477156797.USD","IE00BJT1NW94.SGD","XAO.AU","LU1496350502.SGD","LU1064131342.USD","LU0642271901.SGD","DFII","07500","BITU","BK4550","BTCI","LU0289739343.SGD","LU0742534661.SGD","MHImain","LU1235294995.USD","LU1791710582.SGD","LU0310800965.SGD","IE00BJJMRZ35.SGD","BK4543","XKO.AU","07300","GCPU","IE00BZ1G4Q59.USD","BTCO","BAGY","LU2286300806.USD","BK4585","LU2756315664.SGD","CBOJ","IE0009355771.USD","LU0820561818.USD","BFJL","LU0211331839.USD","XBTY","LU1267930813.SGD","LU1580142542.USD","BTC","LU1804176565.USD","LU2264538146.SGD","BK0278","CBXA","BCCC","DEFI","BTC.USD.CC","IE00B0JY6N72.USD","LU0157215616.USD","82800","BK4505","03037","09115","BTCZ","LU0354030511.USD","LU0980610538.SGD","LU1201861249.SGD","LU0943347566.SGD","LU1226287529.USD","MEDX","GBTC","BK4534","BK0201","BTCL","BITI","BTF","PPH","BK0187","LU0128525689.USD","LU0889565833.HKD","LU0208291251.USD","LU0251131958.USD","ES3.SI","BK4578","LU1267930227.SGD","LU1316542783.SGD","LU1988902786.USD","BK0028","LU1989764748.USD","LU0354030438.USD","CBXO","LU0820562030.AUD","CRMG","SBIT","LU0310799852.SGD","02800","BK4588","LU0719512351.SGD","LU1720051108.HKD","IE00BQXX3F31.USD","LU1551013342.USD","LU2244417387.USD","BK4548","BK4007","CBTY","LU2361045086.USD","LU0067412154.USD","BK4567","LU0109392836.USD","LU2247934214.USD","LU2458330243.SGD","LU2357305700.SGD","LU2461242641.AUD","LU0320765489.SGD","IE00BFTCPJ56.SGD","LU0082616367.USD","LU1807302812.USD","LU0477156953.USD","BTCW","LU0211328371.USD","CBXY","BK4528","LU0501845795.SGD","XJO.AU","BK0188","CBXJ","YBTC","LU0238689110.USD","03419","LU2087625088.SGD","LU1781817850.SGD","LU0234570918.USD","BTRN","IE00BQXX3C00.GBP","CBTO","IE00BKVL7J92.USD","LU0880133367.SGD","LU2756315318.SGD","BK0012","LU1823568750.SGD","NVS","BRRR","LU0057025933.USD","LU1551013425.SGD","LU0072913022.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666324377","title":"US Equity Markets End Lower After Houthi Attack on Saudi Arabia Energy Facilities","url":"https://stock-news.laohu8.com/highlight/detail?id=2666324377","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666324377?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:15","pubTimestamp":1788898507,"startTime":"0","endTime":"0","summary":"US equity indexes ended lower Tuesday after an Iran-backed militia group attacked Saudi Arabian energy sites, pushing crude oil and government bond yields higher.* Yemen's Houthis attacked energy faci","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1061106388.HKD","LU2764263039.SGD","IE000M9KFDE8.USD","LU0320765489.SGD","LU0070302665.USD","BK4007","04332","FTXL","IE00BFTCPJ56.SGD","LU0211331839.USD","LU0149725797.USD","BK4550","LU0056508442.USD","SG9999001440.SGD","SOXX","TBXU","BK4575","BK4535","BK4554","INTW","LU0251142724.SGD","LU1852331112.SGD","BK4602","LU0122379950.USD","LU1023059063.AUD","IE000F7OJYX1.SGD","INT","IE000SO60NU8.SGD","LU2360106780.USD","LU1983299246.USD","IE00BJJMRZ35.SGD","PPH","LU2148611432.USD","BK4543","LU2250418816.HKD","INYY","IE0009355771.USD","BK4529","LU0109394709.USD","LU2357627491.SGD","BK4605","IE0002141913.USD","LU0889565916.HKD","IE00B2B36J28.USD","LU0859254822.USD","LU0868494617.USD","LU1571399168.USD","PJP","IE00B4R5TH58.HKD","BIB","LU0208291251.USD","BK4527","AIQ","LINT","LEGR","LU0081259029.USD","BK4599","LU2244417387.USD","DRIV","LU2764262908.HKD","LU2242646821.SGD","LU0321505439.SGD","PBE","XNTK","INTC","LU0251131958.USD","LU0321505868.SGD","LU0742534661.SGD","IBB","AIS","LU2112291526.USD","BK4139","BK4534","LU0719512351.SGD","LU1057294990.SGD","IE0000B7K699.USD","LU2720916845.USD","LU2543165471.USD","BK4515","LU0289739699.SGD","MEDX","TTEQ","IE000MB6IJN5.SGD","IE000WAW04H5.SGD","04335","BK4588","CHPS","BK4579","LU2089985449.USD","LU0274383776.USD","BBH","LU2931357623.SGD","LU0154236417.USD","IE000BZT7R73.USD","LU0320765992.SGD","SINTCmain","LU2242652126.USD","IE00BJT1NW94.SGD","LU0058720904.USD","BK4532","AMGN","LU2764263203.CNY","HK0000304805.HKD","BK4566","LU2089984988.USD","LU0048573561.USD","BK4612","LU2468319806.SGD","LU0187121727.USD","BK4585","BK4581","NVS","HK0000304797.USD","LU0082616367.USD","QQQA","BK4578","IBBQ","BK4141","BK4533","BK4512","LU0097036916.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666937221","title":"Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for Hsv Helicase-Primase Inhibitor Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2666937221","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666937221?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA4XVZNR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0859254822.USD","SG9999015952.SGD","BIB","BK4550","LU1585245621.USD","BMED","LU1061106388.HKD","LU1934455194.USD","BK4566","LU1934455277.USD","SG9999015978.USD","TMED","LU0823416689.USD","LU0965509283.SGD","LU1023059063.AUD","LU0889565916.HKD","LU1839511570.USD","LU1674673428.USD","LU0058720904.USD","LU2468319806.SGD","IBB","LU1934455863.HKD","LU0122379950.USD","LU0965509010.AUD","LU1430594728.SGD","SG9999015945.SGD","LU2357627491.SGD","MEDI","LU1674673691.USD","TBXU","BK4588","LU1778281490.HKD","IE00B19Z3B42.SGD","LU1037948541.HKD","IE0002270589.USD","ASMB","BBH","IBBQ","SG9999015986.USD","GILD","LU0289739699.SGD","IE00B3T34201.USD","LU0320765992.SGD","LU2089984988.USD","IE00BZ1G4Q59.USD","LU0109394709.USD","LU0234570918.USD","BK4578","IE00B19Z3581.USD","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666437220","title":"Assembly Biosciences - Assembly Bio Eligible for up to $280 Mln in Milestones and Royalties Outside U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2666437220","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666437220?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA4XVZNR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MEDI","LU2089984988.USD","BK4578","BK4568","SG9999015952.SGD","ASMB","IE00BKVL7J92.USD","IE00B3T34201.USD","LU1066053197.SGD","LU1934455863.HKD","LU1674673428.USD","LU1066051498.USD","LU0114720955.EUR","LU1934455194.USD","LU0889565916.HKD","IE00BZ1G4Q59.USD","LU0234570918.USD","LU2324357040.USD","GILD","BBH","LU1023059063.AUD","LU1061106388.HKD","LU0965509101.SGD","LU0058720904.USD","TBXU","TMED","LU1430594728.SGD","BK4550","LU1934455277.USD","BK4532","LU0965509283.SGD","LU0109394709.USD","IE00B19Z3B42.SGD","SG9999015978.USD","LU2112291526.USD","IE00B7SZLL34.SGD","BIB","BK4583","LU2468319806.SGD","IBBQ","BK4139","IBB","BK4588","IE00B19Z3581.USD","LU1585245621.USD","LU1839511570.USD","LU1037948897.HKD","LU1571399168.USD","LU0882574055.USD","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666216372","title":"Assembly Biosciences - Gilead Retains Sole Right for Clinical Development and Commercialization of Hsv Hpi Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2666216372","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666216372?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA4XVZNR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ASMB","IBB","LU0122379950.USD","LU1934455277.USD","BK4583","LU0861579265.USD","LU0058720904.USD","LU0882574055.USD","IE00BKVL7J92.USD","SG9999015978.USD","IE00BSNM7G36.USD","TBXU","TMED","LU1430594728.SGD","LU1674673428.USD","GILD","BK4585","LU1585245621.USD","LU0965509283.SGD","IE0002270589.USD","LU2468319806.SGD","LU0320765992.SGD","LU1066053197.SGD","LU2324357040.USD","LU0234570918.USD","LU0965509010.AUD","LU0859254822.USD","BK4139","LU1037948897.HKD","BK4566","BMED","BK4532","IBBQ","BK4578","BK4568","LU0114720955.EUR","MEDI","LU1934455863.HKD","BK4550","LU0889565916.HKD","BBH","LU1057294990.SGD","LU1934455194.USD","LU2112291526.USD","BIB","LU0109394709.USD","LU1674673691.USD","SG9999015986.USD","LU1839511570.USD","SG9999015945.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666637499","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2666637499","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666637499?lang=en_us&edition=fundamental","pubTime":"2026-09-09 01:57","pubTimestamp":1788890247,"startTime":"0","endTime":"0","summary":"Sigma Lithium's (SGML) mining and industrial operations remain unaffected by a preliminary judicial ruling that allegedly suspends its environmental licenses, the company said Monday.Shares sank more ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BBH","BK4534","TBXU","LU1571399168.USD","BK4532","LU0109394709.USD","LU0211331839.USD","SGML","LU2468319806.SGD","LU0122379950.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0320765992.SGD","BK4566","LU2089984988.USD","MEDX","LU2242652126.USD","PJP","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","BK4581","PBE","BK4599","IBBQ","BIB","LU1023059063.AUD","LU1983299246.USD","LU0889565916.HKD","LU2242646821.SGD","LU1061106388.HKD","SG9999001440.SGD","AMGN","BK4533","IE0009355771.USD","LU0058720904.USD","LU0320765489.SGD","PPH","LU1057294990.SGD","LU0289739699.SGD","BK4585","NVS","IE0002141913.USD","BK4578","LU0868494617.USD","LU0070302665.USD","BK4007","BK4139","BK4588","LU0208291251.USD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374155","title":"Jefferies says definitive readthrough to Sarepta from Novartis news ‘premature’","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374155","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374155?lang=en_us&edition=fundamental","pubTime":"2026-09-09 01:55","pubTimestamp":1788890118,"startTime":"0","endTime":"0","summary":"After Sarepta (SRPT) competitor Novartis (NVS) reported that its Phase 3 HARBOR trial of del-desiran in myotonic dystrophy type 1 failed to achieve...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jefferies-says-definitive-readthrough-to-sarepta-from-novartis-news-premature-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jefferies-says-definitive-readthrough-to-sarepta-from-novartis-news-premature-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","IE0009355771.USD","LU0208291251.USD","SRPU","IE00BJT1NW94.SGD","PPH","BK4578","BK4139","IE00BFTCPJ56.SGD","BK4585","LU0070302665.USD","BK4588","SRPT","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0211331839.USD","MEDX","BK4532","NVS","LU0320765489.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374571","title":"Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Sep 8: Drivers Behind the Movement","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374571","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374571?lang=en_us&edition=fundamental","pubTime":"2026-09-09 01:15","pubTimestamp":1788887735,"startTime":"0","endTime":"0","summary":"• Gilead pulled back due to profit-taking following a sustained multi-month rally.\n• Strong second-quarter revenue was driven by flagship HIV and Trodelvy franchises.\n• Analysts maintain Buy ratings with an average price target of $157.79.","market":"nz","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262156548-market-movers-gild-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1934455277.USD","LU0122379950.USD","LU0289739699.SGD","SG9999015952.SGD","IE00BZ1G4Q59.USD","LU2324357040.USD","LU0109394709.USD","LU2087621335.USD","LU2112291526.USD","LU1061106388.HKD","SG9999015986.USD","IBB","LU0320765992.SGD","LU2468319806.SGD","BK4578","BK4139","LU1585245621.USD","LU1674673691.USD","LU1023059063.AUD","IE00B19Z3581.USD","BK4550","BBH","BK4568","LU0114720955.EUR","LU1778281490.HKD","IE0002270589.USD","LU1066051498.USD","SG9999015978.USD","BIB","LU0965508806.USD","LU2089984988.USD","MEDI","TMED","LU1674673428.USD","IE00BKVL7J92.USD","LU0889565916.HKD","LU1839511570.USD","LU0058720904.USD","LU1571399168.USD","LU1057294990.SGD","IE00B19Z3B42.SGD","TBXU","LU0965509010.AUD","LU1430594728.SGD","LU0234570918.USD","BK4585","LU1934455194.USD","LU1037948541.HKD","LU1037948897.HKD","LU1934455863.HKD","LU2357627491.SGD","SG9999015945.SGD","BK4532","LU1066053197.SGD","BK4583","IE00BSNM7G36.USD","GILD","LU0823416689.USD","LU0861579265.USD","BK4566","LU0965509101.SGD","LU0882574055.USD","BK4588","LU0965509283.SGD","IE00B3T34201.USD","IBBQ","IE00B7SZLL34.SGD","LU0859254822.USD","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374359","title":"Mizuho sees Sarepta selloff on Novartis DM1 miss as overdone","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374359","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374359?lang=en_us&edition=fundamental","pubTime":"2026-09-09 01:10","pubTimestamp":1788887419,"startTime":"0","endTime":"0","summary":"Mizuho analyst Uy Ear believes Sarepta’s (SRPT) selloff due to Novartis’ (NVS) failed HARBOR Phase 3 study of del-desiran in DM1 is overdone. In th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mizuho-sees-sarepta-selloff-on-novartis-dm1-miss-as-overdone-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mizuho-sees-sarepta-selloff-on-novartis-dm1-miss-as-overdone-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0211331839.USD","IE00BJJMRZ35.SGD","SRPU","BK4578","LU0320765489.SGD","NVS","BK4532","LU0208291251.USD","IE00BFTCPJ56.SGD","PPH","MEDX","IE0002141913.USD","IE0009355771.USD","LU0070302665.USD","BK4585","SRPT","BK4139","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666710603","title":"Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2666710603","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666710603?lang=en_us&edition=fundamental","pubTime":"2026-09-09 01:09","pubTimestamp":1788887360,"startTime":"0","endTime":"0","summary":"Amgen's  experimental heart drug olpasiran may still show a meaningful reduction in major cardiovascular events, even after Novartis'  competing drug failed in a large study, UBS Securities said Monday in a report.Novartis' pelacarsen trial came up short overall, though UBS' analysis suggests the drug might have shown a modest benefit of 7% to 11% reduction in heart-attack-and-stroke risk among patients with very high levels of lipoprotein, a cholesterol-like particle linked to heart disease, the report said.Amgen's study focuses on an even higher-risk group, and olpasiran lowers lipoprotein to a greater degree than pelacarsen, UBS said. Amgen's trial also uses a different primary endpoint that excludes stroke, and taken together, these factors may help turn a small numerical benefit into a statistically significant result, potentially around a 15% reduction in major cardiovascular events, the report said.UBS maintained its buy rating on Amgen stock and its $440 price target.Amgen shar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BJT1NW94.SGD","LU2468319806.SGD","BK4566","BBH","IE0009355771.USD","NVS","IE00BFTCPJ56.SGD","BK4534","SG9999001440.SGD","BK4139","BK4533","IBBQ","TBXU","IE00B2B36J28.USD","MEDX","IE0002141913.USD","LU0122379950.USD","LU1023059063.AUD","PPH","BK4599","LU0889565916.HKD","LU2242646821.SGD","BIB","LU0868494617.USD","BK4581","PBE","LU2112291526.USD","LU0211331839.USD","LU1061106388.HKD","LU0058720904.USD","BK4588","AMGN","BK4585","LU0070302665.USD","LU1057294990.SGD","BK4007","IBB","LU1983299246.USD","LU0320765992.SGD","LU2242652126.USD","LU0289739699.SGD","LU2089984988.USD","LU0109394709.USD","IE00BJJMRZ35.SGD","LU0208291251.USD","IE00B4R5TH58.HKD","BK4532","LU1571399168.USD","PJP","BK4578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666717963","title":"Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2666717963","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666717963?lang=en_us&edition=fundamental","pubTime":"2026-09-09 01:00","pubTimestamp":1788886800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA5WKCFL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0965509283.SGD","BK4585","BIB","BK4532","LU1778281490.HKD","LU0823416689.USD","LU2468319806.SGD","IE0002270589.USD","TMED","IE00BZ1G4Q59.USD","LU1934455194.USD","LU1037948897.HKD","LU2089984988.USD","MEDI","LU2357627491.SGD","BK4550","LU1674673428.USD","LU2087621335.USD","LU1023059063.AUD","LU1066051498.USD","BK4566","IE00B19Z3581.USD","LU0859254822.USD","LU1585245621.USD","LU0882574055.USD","SG9999015986.USD","BK4578","BK4583","LU2112291526.USD","IE00B3T34201.USD","LU0320765992.SGD","IBB","GILD","LU1839511570.USD","IE00BSNM7G36.USD","BBH","IE00B7SZLL34.SGD","LU0965508806.USD","LU1066053197.SGD","LU1057294990.SGD","LU2324357040.USD","IE00BKVL7J92.USD","LU0289739699.SGD","TBXU","LU1674673691.USD","LU0234570918.USD","LU1934455863.HKD","IBBQ","LU0122379950.USD","BMED"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":112,"code":"91000000","status":"200"}]}}